Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort...
Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) announced that it has completed the construction of an extensive library of full-length, fully human monoclonal antibodies (mAbs). Initial analysis indicates a potential diversity of more than one trillion unique mAbs. The company believes...
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that primary and secondary endpoints were not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its...
Trius Therapeutics, Inc. announced that on February 26th, 2010, the FDA issued new draft guidance on non-inferiority clinical trials that will apply to the design of the Company's proposed Phase 3 trials for its investigational antibacterial drug torezolid phosphate. Trius is conforming the...
Ark Therapeutics Group plc (AKT: LSE) ("Ark" or "the Company"), announces that it has filed documentation with the European Medicines Agency ("EMA") in relation to its request for re-examination of the marketing approval application ("MAA") for Cerepro®, Ark's novel gene based therapy for the...
Understanding & implementing best practice approaches to value-based sales in the competitive cancer marketplace Conference dates: 15th-16th March, 2010 Venue: Brussels, Belgium This will be the only event looking at "best practice" approaches to selling and marketing high-value cancer drugs...
Regulus Therapeutics Inc. announced that new pre-clinical data from multiple therapeutic programs were presented at the "RNA Silencing: Mechanism, Biology and Application" Keystone Symposium held January 14 - 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing...
Regulus Therapeutics Inc. announced that new pre-clinical data from multiple therapeutic programs were presented at the "RNA Silencing: Mechanism, Biology and Application" Keystone Symposium held January 14 - 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing...
Regulus Therapeutics Inc. announced that new pre-clinical data from multiple therapeutic programs were presented at the "RNA Silencing: Mechanism, Biology and Application" Keystone Symposium held January 14 - 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing...
Funxional Therapeutics Ltd (Funxional) has announced the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L, an orally available small molecule that belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs). Following the successful...
Oraya Therapeutics, Inc., announced that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The groundbreaking clinical trial is being...
Novelos Therapeutics' (NVLT.OB) CEO Is Eyeing "Revolutionary" Phase III Study Results
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive...
Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
More...
Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
More...